{"id":"bevacizumab-biosimilar-ibi305-plus-sintilimab","safety":{"commonSideEffects":[{"rate":"null","effect":"Hypertension"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bevacizumab Biosimilar IBI305 works by binding to VEGF-A, preventing its interaction with its receptor and thereby inhibiting angiogenesis. Sintilimab, on the other hand, binds to PD-1, preventing its interaction with PD-L1 and thereby enhancing T-cell activation and anti-tumor immune response.","oneSentence":"Bevacizumab Biosimilar IBI305 is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while sintilimab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:18.225Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Colorectal cancer"}]},"trialDetails":[{"nctId":"NCT07007767","phase":"PHASE2","title":"Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-15","conditions":"Colorectal Cancer Metastatic","enrollment":32},{"nctId":"NCT05713994","phase":"","title":"Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Ze-yang Ding, MD","startDate":"2020-05-19","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT06667050","phase":"PHASE2","title":"CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"West China Hospital","startDate":"2024-10-10","conditions":"Gastric Adenocarcinoma","enrollment":58},{"nctId":"NCT04735861","phase":"PHASE2","title":"Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma","status":"COMPLETED","sponsor":"Tongji Hospital","startDate":"2021-04-07","conditions":"Ovarian Clear Cell Carcinoma","enrollment":38},{"nctId":"NCT05717738","phase":"","title":"Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-01-20","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT05029973","phase":"PHASE2","title":"HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-05-10","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT05617430","phase":"PHASE2","title":"Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-11-02","conditions":"Hepatocellular Carcinoma","enrollment":43},{"nctId":"NCT05251662","phase":"PHASE2","title":"Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-01-13","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Byvasda (B) plus S"],"phase":"phase_2","status":"active","brandName":"Bevacizumab Biosimilar IBI305 plus sintilimab","genericName":"Bevacizumab Biosimilar IBI305 plus sintilimab","companyName":"Ze-yang Ding, MD","companyId":"ze-yang-ding-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab Biosimilar IBI305 is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while sintilimab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction. Used for Non-small cell lung cancer, Colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}